bluebird bio Inc (NASDAQ:BLUE) CEO Nick Leschly sold 5,435 shares of the business’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $173.38, for a total value of $942,320.30. Following the transaction, the chief executive officer now owns 171,009 shares in the company, valued at $29,649,540.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Nick Leschly also recently made the following trade(s):
- On Wednesday, December 13th, Nick Leschly sold 117,500 shares of bluebird bio stock. The shares were sold at an average price of $184.08, for a total value of $21,629,400.00.
- On Wednesday, November 1st, Nick Leschly sold 2,127 shares of bluebird bio stock. The shares were sold at an average price of $145.17, for a total value of $308,776.59.
- On Friday, October 20th, Nick Leschly sold 3,350 shares of bluebird bio stock. The shares were sold at an average price of $145.02, for a total value of $485,817.00.
- On Monday, October 23rd, Nick Leschly sold 7,050 shares of bluebird bio stock. The shares were sold at an average price of $145.14, for a total value of $1,023,237.00.
- On Tuesday, October 17th, Nick Leschly sold 10,823 shares of bluebird bio stock. The shares were sold at an average price of $145.05, for a total value of $1,569,876.15.
bluebird bio Inc (BLUE) opened at $204.90 on Thursday. bluebird bio Inc has a 1-year low of $67.10 and a 1-year high of $222.03.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. During the same period in the prior year, the company posted ($2.07) EPS. The firm’s quarterly revenue was up 397.4% compared to the same quarter last year. research analysts predict that bluebird bio Inc will post -6.71 EPS for the current year.
Several equities research analysts have recently weighed in on the company. BidaskClub upgraded bluebird bio from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 26th. Leerink Swann lowered bluebird bio from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $162.00 to $194.00 in a research note on Thursday, January 25th. Oppenheimer reiterated a “hold” rating on shares of bluebird bio in a research note on Tuesday, January 9th. CIBC assumed coverage on bluebird bio in a research note on Thursday, December 21st. They issued a “market perform” rating on the stock. Finally, Maxim Group lowered bluebird bio from a “buy” rating to a “hold” rating and set a $200.00 price objective on the stock. in a research note on Wednesday, December 13th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $159.05.
Large investors have recently bought and sold shares of the business. QS Investors LLC lifted its holdings in bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in bluebird bio by 454.2% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after buying an additional 813 shares in the last quarter. Biondo Investment Advisors LLC acquired a new position in bluebird bio during the 3rd quarter worth $203,000. SG Americas Securities LLC raised its position in shares of bluebird bio by 17.9% during the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 295 shares during the last quarter. Finally, Fairfield Bush & CO. bought a new stake in shares of bluebird bio during the 2nd quarter valued at $210,000.
COPYRIGHT VIOLATION NOTICE: “bluebird bio Inc (BLUE) CEO Nick Leschly Sells 5,435 Shares” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/01/bluebird-bio-inc-blue-ceo-sells-942320-30-in-stock.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.